Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study

Xiang-Chong Luo, Peng Tang, Pei-Xiong Zhong · 2024

Read Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study by Xiang-Chong Luo, Peng Tang, Pei-Xiong Zhong (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625108.txt.

Description

Xiang-Chong Luo, Peng Tang, and Pei-Xiong Zhong review one hundred fifty lung cancer patients to see what a vessel-blocking drug adds to chemoradiation, in a 2024 study. The drug, bevacizumab, starves tumors by cutting their blood supply signal. Serum levels of two growth signals and one regulatory RNA were compared before and after treatment, and patients were split by how well they responded.

After treatment, both growth signals fell and the RNA rose, more so in the drug group than in controls, matching a higher response rate. Statistical modeling named three independent drivers of success: how long the disease had run, tumor diameter, and the treatment regimen itself. The authors conclude the combination works better and safely, and they advise weighing those three factors when planning therapy. The study is retrospective, from one hospital's records.

Catalog record

CREATORXiang-Chong Luo, Peng Tang, Pei-Xiong Zhong
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11625108

Browse the full library · About the Tower of Babel